Kovitz Core Equity ETF EQTY
30.35 USD +0.64 (+2.15%)
Nov 4, 2026, 10:30 AM EST
30.26 Day range 30.35
24.74 52-week range 30.35
- YTD
- +12.45%
- 1 year
- +17.23%
- Market cap
- 1.40B
- EPS (ttm)
- 1.12
- P/E ratio
- 27.13
- YTD return
- +12.45%
- 1-year return
- +17.23%
- Volume
- 848.64K
- Avg volume
- 59.34K
- Open
- 30.35
- Previous close
- 29.71
- Day's range
- 30.26 – 30.35
- 52-week range
- 24.74 – 30.35
2Y +6.36 (+27.24%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 29.40
- 200-day average
- 28.05
Next earnings
Consensus EPS estimate 0.00.
About Kovitz Core Equity ETF
The fund invests primarily in equity securities of U.S. and foreign companies. Equity securities in which the fund may invest include common stocks and common stock equivalents (such as rights or warrants, which give the fund the ability to purchase the common stock, and convertible securities, which are securities that are convertible into the common stock). The fund may invest in companies of any market capitalization, including small- and mid-capitalization companies.
News
Billionaire Investor Adds to Danaher Stake After Cutting It Earlier This Year
Danaher Brings NVIDIA AI Into Scientific Instruments in Push for Faster Discoveries
EXCLUSIVE: IRS Targets Section 351 ETF Tax Strategy: What Investors Need To Know
EXCLUSIVE: IRS Targets Section 351 ETF Tax Strategy: What Investors Need To Know
Analog Devices to Buy Alif Semiconductor for $1.35 Billion
Aon Bets $17B On USI To Strengthen US Middle-Market Business
Motorola Solutions Buys D-Fend For $1.5 Billion Deal
Equity Metals Provides Corporate Update
Equity Metals Announces Crews and Drill Mobilized to Commence Winter '26 Program on the Silver Queen Ag-Au Property, British Columbia; Arlington Property Drill Results Evaluated
Becton, Dickinson Wins FDA Clearance For Next-Gen Breast Biopsy Device, Launch Set For 2026
Your note
Sign in to keep a note on EQTY — it syncs with the Stock Master app.
